Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $220000.0.

  • Precision Biosciences' Change in Account Payables rose 21827.96% to $220000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $385000.0, marking a year-over-year increase of 33333.33%. This contributed to the annual value of -$2.1 million for FY2024, which is 23899.2% down from last year.
  • Precision Biosciences' Change in Account Payables amounted to $220000.0 in Q3 2025, which was up 21827.96% from $199000.0 recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Change in Account Payables ranged from a high of $2.0 million in Q4 2023 and a low of -$2.1 million during Q1 2024
  • Its 5-year average for Change in Account Payables is $39210.5, with a median of $72000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Precision Biosciences' Change in Account Payables was 70833.33% (2022), while the steepest drop was 59310.34% (2022).
  • Quarter analysis of 5 years shows Precision Biosciences' Change in Account Payables stood at $627000.0 in 2021, then tumbled by 45.77% to $340000.0 in 2022, then skyrocketed by 489.12% to $2.0 million in 2023, then tumbled by 96.41% to $72000.0 in 2024, then surged by 205.56% to $220000.0 in 2025.
  • Its Change in Account Payables was $220000.0 in Q3 2025, compared to $199000.0 in Q2 2025 and -$106000.0 in Q1 2025.